Advertisement
A vs BSX
Which Stock Would AI Choose? Agilent Technologies (A) vs. Boston Scientific (BSX) Stock Comparison
Key Takeaways
- A has delivered positive year-to-date returns exceeding 10%, while BSX has experienced sharp declines of over 30% year-to-date.
- In recent market activity, A posted monthly gains around 9%, contrasting BSX's roughly 10% drop over the same period.
- Both stocks operate in the healthcare sector, but A benefits from steadier instrument demand, while BSX faces higher volatility from device approvals and procedure volumes.
- A shows stronger recent momentum and stability, positioning it favorably amid sector rotations.
- Investor sentiment leans toward A for relative performance, though BSX holds growth potential from upcoming earnings.
Introduction
Agilent Technologies (A) and Boston Scientific (BSX) represent key players in the healthcare technology space, with A focusing on precision instruments for life sciences and diagnostics, and BSX specializing in medical devices for cardiovascular and endoscopic procedures. This stock comparison is particularly relevant for investors and traders navigating the medtech sector, where innovation drives growth but regulatory and economic factors create volatility. By examining recent performance, business models, and market positioning, readers can assess relative strengths in today's environment of shifting healthcare spending and technological advancements.
A Overview and Recent Performance
Agilent Technologies (A) is a global leader in laboratory instruments, software, services, and consumables for the life sciences, diagnostics, and applied chemical markets. The company supports pharmaceutical, biopharma, clinical, and academic research with solutions like chromatography systems and mass spectrometry tools. In recent weeks, A shares have rebounded, rising about 9% over the past month following a post-earnings dip influenced by mixed quarterly results. Broader sentiment has improved due to steady demand in biopharma tools and collaborations in cancer research, contributing to year-to-date gains over 10%. Trading around $121 within a 52-week range of $99 to $160, the stock reflects resilience amid sector pressures.
BSX Overview and Recent Performance
Boston Scientific (BSX) develops and manufactures medical devices for minimally invasive procedures, focusing on cardiology, rhythm management, endoscopy, and neuromodulation. Its portfolio includes stents, pacemakers, and ablation systems used in hospitals worldwide. Recent market activity has pressured BSX, with shares declining around 10% in the past month and over 30% year-to-date, trading near $61 in a 52-week range of $61 to $110. Analyst downgrades and softer procedure volumes have weighed on performance, though anticipation for quarterly earnings adds near-term focus. Sentiment reflects challenges from economic headwinds affecting elective procedures.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from over 350 bots that trade thousands of tickers across stocks, ETFs, and crypto. These bots employ diverse strategies like swing trading, day trading, and multi-asset approaches, with timeframes from 5 minutes to several days. Only the most suitable for current market conditions earn a spot in this dynamic section of 25 bots, selected via AI analysis for real-time signals, risk management, and outperformance potential. Featured bots display impressive stats, including annualized returns from 50% to over 100%, win rates of 56% to 88%, profit factors up to 6.94, and profit-to-drawdown ratios exceeding 8. Traders can explore virtual agents, single-stock focus, or sector-specific plays like semiconductors and industrials. Visit Trending AI Robots to discover bots matching your style.
Head-to-Head Comparison
Agilent (A) and Boston Scientific (BSX) both thrive in healthcare but diverge in models: A emphasizes recurring revenue from instruments and services, offering stability, while BSX relies on device innovation and procedure growth, introducing higher volatility. Growth drivers for A include biopharma R&D demand, contrasting BSX's exposure to cardiology expansions and regulatory approvals. Recent momentum favors A with upward trends, versus BSX's declines amid economic sensitivity. Risk factors highlight BSX's greater beta to healthcare spending cycles, while A shows lower drawdowns. Market sentiment positions A as defensive, BSX as cyclical.
Tickeron AI Verdict
Tickeron’s AI currently favors A over BSX, driven by stronger trend consistency, positive relative performance, and lower volatility in recent market activity. A's rebound and year-to-date gains signal better stability and catalysts in diagnostics demand, while BSX lags amid downward pressure. This positioning suggests higher probability of near-term outperformance for A in the current environment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Hold and BSX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
A’s FA Score shows that 1 FA rating(s) are green whileBSX’s FA Score has 0 green FA rating(s).
- A’s FA Score: 1 green, 4 red.
- BSX’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
A’s TA Score shows that 5 TA indicator(s) are bullish while BSX’s TA Score has 4 bullish TA indicator(s).
- A’s TA Score: 5 bullish, 4 bearish.
- BSX’s TA Score: 4 bullish, 4 bearish.
Price Growth
A (@Medical Specialties) experienced а -4.21% price change this week, while BSX (@Medical/Nursing Services) price change was -5.25% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +8.27%. For the same industry, the average monthly price growth was +4.48%, and the average quarterly price growth was -5.63%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +0.46%. For the same industry, the average monthly price growth was -2.64%, and the average quarterly price growth was -3.18%.
Reported Earning Dates
A is expected to report earnings on May 27, 2026.
BSX is expected to report earnings on Jul 29, 2026.
Industries' Descriptions
@Medical Specialties (+8.27% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (+0.46% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| A | BSX | A / BSX | |
| Capitalization | 31.9B | 78.9B | 40% |
| EBITDA | 1.82B | 5.49B | 33% |
| Gain YTD | -16.808 | -44.352 | 38% |
| P/E Ratio | 24.89 | 22.20 | 112% |
| Revenue | 7.07B | 20.6B | 34% |
| Total Cash | 1.76B | 1.45B | 121% |
| Total Debt | 3.35B | 11B | 30% |
A | BSX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 69 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 19 Undervalued | 66 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 84 | |
SMR RATING 1..100 | 45 | 56 | |
PRICE GROWTH RATING 1..100 | 62 | 65 | |
P/E GROWTH RATING 1..100 | 56 | 98 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
A's Valuation (19) in the Biotechnology industry is somewhat better than the same rating for BSX (66) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BSX’s over the last 12 months.
BSX's Profit vs Risk Rating (84) in the Medical Specialties industry is in the same range as A (100) in the Biotechnology industry. This means that BSX’s stock grew similarly to A’s over the last 12 months.
A's SMR Rating (45) in the Biotechnology industry is in the same range as BSX (56) in the Medical Specialties industry. This means that A’s stock grew similarly to BSX’s over the last 12 months.
A's Price Growth Rating (62) in the Biotechnology industry is in the same range as BSX (65) in the Medical Specialties industry. This means that A’s stock grew similarly to BSX’s over the last 12 months.
A's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for BSX (98) in the Medical Specialties industry. This means that A’s stock grew somewhat faster than BSX’s over the last 12 months.
| A | BSX | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 81% |
| Stochastic ODDS (%) | 1 day ago 55% | 1 day ago 56% |
| Momentum ODDS (%) | 1 day ago 63% | 1 day ago 49% |
| MACD ODDS (%) | 1 day ago 74% | 1 day ago 58% |
| TrendWeek ODDS (%) | 1 day ago 64% | 1 day ago 52% |
| TrendMonth ODDS (%) | 1 day ago 65% | 1 day ago 56% |
| Advances ODDS (%) | 8 days ago 61% | 8 days ago 58% |
| Declines ODDS (%) | 4 days ago 62% | 4 days ago 53% |
| BollingerBands ODDS (%) | 1 day ago 71% | 1 day ago 61% |
| Aroon ODDS (%) | 1 day ago 59% | 1 day ago 58% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| QMOM | 79.89 | 0.70 | +0.88% |
| Alpha Architect US Quantitative Momt ETF | |||
| MMLG | 36.07 | 0.16 | +0.45% |
| First Trust Multi-Manager Large Gr ETF | |||
| RTRE | 24.91 | 0.02 | +0.10% |
| Rareview Total Return Bond ETF | |||
| IBMS | 25.81 | -0.03 | -0.12% |
| iShares iBonds Dec 2030 Term Mun Bd ETF | |||
| EAGL | 32.38 | -0.10 | -0.31% |
| Eagle Capital Select Equity ETF | |||
A and
Correlation & Price change
A.I.dvisor indicates that over the last year, A has been closely correlated with MTD. These tickers have moved in lockstep 86% of the time. This A.I.-generated data suggests there is a high statistical probability that if A jumps, then MTD could also see price increases.